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Abstract
The gp130-cytokine system has been fertile ground for protein structure–function studies aimed at elucidating the basis of ligand
recognition and receptor activation. A number of longstanding questions involve the mechanism of the stepwise assembly of the active
signaling complexes, as well as the structure of the gp130-cytokine complexes. It has been clear from functional studies that the paradigm of
gp130-cyokine recognition will differ substantially from the classical homo-dimeric systems, typified by human growth hormone (hGH) and
its receptor. Recently, a crystal structure of a viral interleukin-6 (vIL-6), complexed with the D1D2D3 domains of the gp130 extracellular
domain, has resolved many of these questions, and reconciled much of the functional and mutagenesis data which have existed for a variety
of gp130-cytokines. In this review, we discuss the structure of the vIL-6/gp130 complex in some detail and suggest that the geometry of this
complex will be a common structural template utilized by other gp130-cytokines, as well as cytokines from distinct signaling systems.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Receptor/ligand interactions: cross-reactivity as an
emerging paradigm
The ligand-mediated clustering of cell-surface receptor
extracellular domains into unique macromolecular geome-
tries, which elicit defined intracellular signaling cascades,
has emerged as a central paradigm in biology as a means for
a cell to respond to its environment [1]. The specificity of
these receptor/ligand interactions can be exquisite, in order
to ensure tightly regulated physiological responses. How-
ever, many of these receptor systems exhibit an extraordinary
degree of cross-reactivity for diverse ligands, which can
result in a redundancy beneficial for survival of the organ-
ism. This type of cross-reactivity is integral to cell growth
and proliferation (cytokines) [2], neural development (sem-
aphorins, ephrins) [3], innate and adaptive immune
responses (T cell receptor, Toll) [4], host–pathogen inter-
actions (chemokines) [5], as well as many intracellular sig-
naling pathways (JAK/STAT, TRAFF/TRADD, etc.) [6]. In
particular, many cyokines utilize ‘‘shared’’ signaling recep-
tors which, then, inherently require a high degree of cross-
reactivity for their cytokine ligands within a presumably
restricted architecture for complex formation [7]. To date,
there is very little structural information about the extrac-
ellular, higher-order signaling assemblies from shared-recep-
tor systems. This review focuses on a cross-reactive signal-
ing receptor (gp130) and the insight we have gained about an
overall framework for gp130-cytokine/receptor interactions
based on structural studies of viral interleukin-6 (vIL-6)
bound to gp130.
2. The hematopoietic cytokine superfamily
Cytokines (f 200 amino acids) comprise one of the
largest groups of extracellular regulatory molecules, and
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are particularly important pleiotropic intercellular mediators
of a diverse spectrum of vital physiological functions [8].
They are generally involved in induction of immune
responses, cellular proliferation, differentiation, and apop-
tosis [8]. Specific cytokines regulate biological processes
including hematopoiesis, neuronal growth, angiogenesis,
host defense, and pro-inflammatory responses. Due to their
critical roles in these functions, cytokines have utility in the
treatment of human diseases, and a number of them (e.g.
erythropoetin, interleukin (IL)-2, interferon (IFN), etc.) are
currently clinically useful pharmaceuticals [9]. Numerous
structural studies (>10 X-ray structures of uncomplexed
cytokines) have confirmed the four-helix bundle, up-up-
down-down fold (A-B-C-D) common to the haematopoietic
cytokine superfamily [10] (Fig. 1). Cytokines carry out their
functions through interaction with cell-surface receptors
containing a ‘‘cytokine-binding homology region’’ (CHR)
consisting of tandem fibronectin-III domains [10–12]. A
small group of cytokines, of which human growth hormone
(hGH) is a classical system, homo-dimerize a single receptor
subunit [13]. Crystallographic studies of cytokine/receptor
complexes from these homo-dimeric systems (hGH, eryth-
ropoietin (EPO), granulocyte colony-stimulating factor
(GCSF), IFN, etc.) have established a paradigm that cyto-
kines utilize their helical faces as receptor binding epitopes
to interact with the CHR’s of the receptor extracellular
domains [14–20]. However, the majority of cytokines
require hetero-oligomerization of nonsignaling, cytokine-
specific receptors with ‘‘shared’’ signal-transducing recep-
tor(s) [7]. There is currently little biophysical information
for these systems due to the technical difficulties of assem-
bling the larger, hetero-oligomeric receptor complexes.
3. The gp130 system
The gp130-cytokines, also called the ‘‘IL-6 family,’’
encompass the largest group of cytokines which utilize
shared receptors in hetero-oligomeric signaling complexes
[7,21–23]. Gp130 is a signal-transducing receptor which is
shared by IL-6, IL-11, ciliary neurotrophic factor (CNTF),
cardiotrophin (CT-1), leukemia inhibitory factor (LIF), on-
costatin (OSM), and NNT-1/BSF3 (Fig. 1). Until the recent
structure of a vIL-6/gp130 complex, there has existed no
structural information on the receptor/ligand complexes.
These gp130-cytokines mediate a wide variety of both
overlapping and unique biological responses in vivo, across
many tissue systems [7,24,25]. Gp130 signaling is critical to
the normal growth and differentiation of haematopoetic
cells, bone, neurons, muscle, heart, adipose tissue, liver,
and testes. Gp130-cytokines have been implicated in a large
number of diseases and neoplastic disorders, such as multi-
ple myeloma [7]. Targeted inactivation of the gp130 gene in
mice results in a prenatal lethal phenotype. The activities of
gp130-cytokines are mediated through formation of oligo-
meric complexes containing one or more copies of gp130,
which leads to intracellular activation of src and JAK/Tyk
tyrosine kinases (JAKS 1 and 2) as well as the STAT family
of transcription factors (1 and 3) [7,22,26]. The JAK/STAT
profiles elicited by gp130-cytokines lead to characteristic
repertoires of downstream cellular responses.
In contrast to other highly specific hematopoietic recep-
tors, the gp130 cytokine-binding sites are extremely cross-
reactive, with the ability to interact with multiple cytokines
of low sequence homology (10–20%). The gp130-contact
residues on the surfaces of the different cytokines are
composed of almost entirely different amino acids. As a
shared receptor, gp130 may be endowed with unique
physicochemical properties which predisposes it to cross-
reactivity. Hence, a fundamental question in this system,
which is as important to answer as the structural issues, is
whether there exists a common thermodynamic solution for
binding to a cross-reactive receptor. Given that there is
likely a common signaling template combined with the
limited sequence homologies of the cytokines, it seems
probable that each gp130-cytokine interacts with gp130
with a unique energetic landscape.
Extensive structure–function studies on gp130-cytokines
have revealed that gp130 engagement occurs through three
conserved receptor-binding epitopes on the cytokines, the
third (site III) of which is not found in growth hormone-type
cytokines (e.g. hGH, EPO, TPO, PRL, PL) (Fig. 2) [21,27–
30]. While there is only one X-ray structure of a gp130-
cytokine receptor complex [31], there are structures of a
number of uncomplexed gp130-cytokines, including human
IL-6, CNTF, LIF, OSM, and the related IL-12 p35/p40
hetero-dimer [32–36]. The minor degree of sequence con-
servation between these cytokines resides within the helical
cores, while the surfaces of the helices which bind gp130
are unique. Exhaustive mutagenesis of these cytokines, IL-6
Fig. 1. Known structural information for gp130 and gp130-cytokines prior
to structure determination of the vIL-6/gp130 complex. The cytokine X-ray
structures are human IL-6, CNTF, LIF, and OSM [32–35], and the gp130-
D2D3 is from Ref. [38].
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in particular, have defined the locations of the site I, site II,
and site III epitopes (Fig. 2B) [21]. In general, site I is
located on the B and D helical faces, and site II is located on
the A and C helical faces. Site III for all gp130 cytokines is
less well defined but appears to reside at the tip of the four-
helix bundle, the N-terminus of the C-helix (Fig. 2B). The
overall topologies of receptor engagement for all gp130-
cytokines are almost certainly similar, given the similar
locations of the receptor binding sites [37].
The extracellular domain of gp130 is approximately 597
amino acids, which is divided into five fibronectin-III
domains plus a sixth N-terminal domain which is Ig-like
(Figs. 1 and 2). The only structure information available for
gp130 until recently was an X-ray structure of the uncom-
plexed D2D3 domains (i.e. the CHR), which is highly
similar to other CHR structures determined (Fig. 1) [38].
Cytokine engagement by the gp130 extracellular region
occurs through three membrane-distal, h-sheet sandwich
domains (D1D2D3), while the three membrane-proximal
fibronectin type-III domains do not play a specific role in
recognition [38]. By analogy to other hematopoietic cytokine
receptors, gp130 is presumed to recognize ligand through its
classical CHR [10], containing the characteristic pattern of
cysteines and signature WSXWS box, located at domains 2
and 3 (D2D3), respectively (Fig. 2A,B) [21,29,30]. How-
ever, gp130 uniquely requires an additional N-terminal (D1)
Ig-like activation domain (IgD) in order to be functionally
responsive to cytokine [39].
In contrast to the simpler, homo-dimeric hGH (and EPO)
systems (Fig. 2A) [17–19], activated gp130 is a hetero-
oligomeric complex which is formed in a stepwise, hier-
archical fashion (Fig. 2A,B) [21,29,30,37,40]. IL-6, the
most extensively studied of the gp130 cytokines, must first
complex with the CHR (D2D3) of a specific, nonsignaling
a-receptor (termed IL-6Ra, or the ‘‘low affinity receptor’’
KDf 10 nM), through a ‘‘site I’’ epitope, to acquire the
ability to bind gp130 [7]. This binary complex of IL-6 and
Ra, then, forms a composite epitope, termed ‘‘site II’’,
which interacts with the CHR of Gp130 (D2D3 domains)
to form an intermediate trimolecular complex which is not
competent for signaling (Fig. 2).
The transition to a higher-order signaling assembly is a
second defining feature of gp130-cytokines, and is mediated
through a functional interaction between the unique third
receptor-binding epitope (site III) and the gp130 activation
domain (D1 or IgD) [28,39,41,42]: it has not been known
whether there is a direct structural interaction. Full activa-
tion requires a sequential and cooperative recruitment of the
site III and IgD into the intermediate complex to form the
activated receptor cluster (KDf 10 pM). The topology of
the activated assembly has been the subject of extensive
speculation and modeling (Fig. 2D) [21,29,30,37,40]. A
long-standing question is the role of the site III of the
cytokine and D1 of gp130 in assembling the activated
receptor.
4. A common template for assembly
A number of functional studies indicate that IL-6 and IL-
11 signaling complexes are either ‘‘hexamers’’ containing
two copies of cytokine, Ra, and gp130 (2:2:2), or tetramers
[40,43–45]. There is controversy about how the three gp130
epitopes can be simultaneously satisfied in a signaling
complex, and speculative models have been constructed
(Fig. 2D) [21,30,46]. Since the functional epitopes (sites I,
II, and III) of all gp130-cytokines are in similar locations, it
is likely that each signaling assembly will be constructed
from a common oligomeric arrangement, but will differ in
the compositions of the ligand-specific components [47]. It
is clear that a precise relative orientation of the receptor
Fig. 2. Similarities and differences between the typical homo-dimeric
cytokine hGH and the gp130-cytokine IL-6. (A) hGH homo-dimerizes two
identical CHR receptors via sites I and II, where these sites were originally
defined [15]. (B) IL-6 requires pre-complexation with its Ra prior to
interaction with gp130, where the site III interaction assembles the hexamer.
(C) vIL-6 can bind and activate gp130 in an ‘‘Ra-independent fashion’’.
(D) Topological models of the active signaling template for human IL-6.
These models have been postulated by various groups, and are reviewed in
detail in the following publications: Refs. [21,30,37,40,46].
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ectodomains is necessary for activation: simple clustering
with antibodies will not suffice, as the frequency of agonist
antibodies is extremely low. As the EPO receptor studies
have demonstrated, subtle perturbations in the extracellular
complex geometry can qualitatively change the downstream
signaling [48,49]. The architecture of the higher-order
signaling assembly of IL-6, IL-6Ra, and gp130 should
provide a structural template upon which the signaling
complexes for other members of this large family can be
directly inferred.
5. vIL-6
An important new member of the gp130-cytokine family
is a viral-derived IL-6. Kaposi-sarcoma herpesvirus (KSHV,
or HHV8) is a recently discovered g herpesvirus which is a
likely causative factor for the development of Kaposi
sarcoma (KS), as well as other neoplastic diseases associ-
ated with KS, such as pleural effusion lymphoma and multi-
centric Castleman’s disease [50]. KSHV encodes a func-
tional homologue of IL-6, termed vIL-6, which has f 22%
sequence identity to human IL-6. vIL-6 is expressed in KS-
infected cells and is a multi-functional cytokine which is
able to induce angiogenesis, hematopoiesis, and plasmacy-
tosis [51]. In vivo studies have indicated that vIL-6 plays an
important role in KSHV-associated disorders, including
AIDS [51]. Therefore, vIL-6 is a candidate for a paracrine
growth factor in the bone marrow microenvironment, sug-
gesting a molecular mimicry in the oncogenesis of some
lymphoproliferative disorders. As for human IL-6, which
plays important roles in the development of a number of B
cell neoplastic disorders, vIL-6 has direct involvement in
human disease pathogenesis. Hence, this is a clear example
of receptor cross-reactivity having human health consequen-
ces.
A striking feature of vIL-6 is that it has bypassed the
human IL-6 (huIL-6) requirement for an a-receptor (Ra) to
activate gp130: vIL-6 directly activates gp130 on cells
which do not express an Ra (Fig. 2C) [52]. Nonetheless,
vIL-6 activation of gp130 initiates similar downstream
signaling cascades involving JAK1 and activation of
STATs1 and 3 [53]. vIL-6 has therefore evolved a binding
interaction with gp130 of sufficient stability to dispense
with Ra, yet elicit the same functional consequences. The
low sequence homology between viral and human IL-6
indicates that different amino acids will be used to bind
gp130, which further highlights the remarkable ability of
gp130 to cross-react with cytokines with widely divergent
surface properties. vIL-6 is a ‘‘naturally designed’’ variant
which is of tremendous utility to probe gp130 cross-
reactivity. vIL-6 provides us with the opportunity to eluci-
date the structural basis of molecular mimicry of the human
cytokine by a viral homolog [54]. Further, by comparing the
architectures of the human IL-6 and viral IL-6 signaling
assemblies, we can determine whether gp130 requires an
identical orientation in the complexes to elicit the same
downstream effectors, or whether the orientations have
diverged.
6. Structural biology of the vIL-6/gp130 complex
Given the similarities of action of human versus viral IL-6,
we surmised that both cytokines would utilize a common
structural template to assemble the active signaling complex
[31]. This template would likely be similar for all gp130-
cytokines in that they share gp130 as a common signaling
receptor. We have therefore embarked on a program to study
the structural relationships between the human and viral
cytokine so that we might decipher the structure of this
template. In order to reconstitute the gp130-cytokine ‘‘acti-
vation complex,’’ we expressed the three N-terminal domains
of gp130 (i.e. the CHR plus IgD) in insect cells (note nomen-
clature: D1 = IgD, D2D3 =CHR, and D1D2D3 = IgD–CHR,
will be used throughout text interchangeably). The vIL-6
and gp130 formed a stoichiometric, stable complex whose
mass was determined by gel filtration and analytical ultra-
centrifugation to be approximately 126 kDa (theoretical
mass: 131.5 kDa). This mass indicates the presence of a
2:2 ratio of gp130 to vIL-6.
To assess the relevance to the human IL-6 complex, we
expressed the same gp130 construct with human IL-6 and
IL-6Ra to form an equally stable complex of MW f 193
kDa, indicating a 2:2:2 stoichiometry (theoretical mass:
191.6 kDa) [45]. The mass difference between the vIL-6/
gp130 and huIL-6/Ra/gp130 complexes (f 60 kDa) is
accounted for by the two Ra (2f 30 kDa) not present
in the vIL-6 complex. Hence, the Ra-independence of vIL-
6, previously demonstrated in cellular experiments, is reca-
pitulated with our soluble molecules. Does this ‘‘tetramer’’
bear a resemblance to the human hexamer? In order to
answer this question, we determined the crystal structure of
the viral/IL-6/gp130D1D2D3 tetramer [31].
7. Highlights of the structure
The structure of the complex assumes a novel ‘‘ham-
mock-like’’ configuration containing a tetrameric arrange-
ment of two vIL-6 molecules and two human gp130
receptors (approximate dimensions 95 56 65 A˚) (Fig.
3) [45]. The complex is tethered together through the
interaction of one face of vIL-6 (site II) with a gp130
CHR (D2D3), and a second epitope (site III) at the tip of
the vIL-6 four-helix bundle interacting with the IgD (D1)
domain of a second gp130 from the other half of the
tetramer (Fig. 3). The ligand-specific interactions form a
top ‘‘canopy’’ of the complex supported underneath by the
D3 domains of gp130. It is clear from this structure that the
D1 domain is essential for the formation of the activated,
higher-order assembly. The site II interface between the
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gp130 CHR and the vIL-6 interlocks the complex together
with the site III interface involving the D1 domain. As seen
from the top (Figs. 3B and 6A), the overall configuration
results in a large hole in the middle of the complex
(f 16 45 A˚), a spacing likely critical for the gp130
extracellular domains to orient the intracellular domains
correctly for signal propagation. In contrast to other cyto-
kine receptor complexes where the receptor C-termini are
within close proximity to each other as they enter the
membrane, the gp130 C-termini are held far apart (85 A˚),
although the three fibronectin type III (FN-III) domains
leading to the membrane could close the gap, as predicted
from functional studies. The macromolecular architecture of
the vIL-6/gp130 tetramer is novel for cytokine–receptor
complexes, and represents a previously unseen mode of
receptor activation mediated by the IgD. A question which
remains is the disposition of the D4D5D6 domains leading
to the membrane. Will they angle back towards each other,
or will they maintain the large distance between the two
gp130 molecules as they enter the membrane? Further
structural studies of full-length ectodomain fragments of
gp130 will be required to address these questions.
8. Structure of gp130
The recombinant material used for crystallization of this
complex was not glycosylated at the Asn-linked positions.
We know that the D1D2D3 domains of gp130 contain a
total of six linkages [55], however, their elimination did not
effect the interactions with cytokines. The active extracel-
lular fragment of gp130, comprising the N-terminal D1 (also
called IgD, or activation domain) and the CHR at D2 and
D3, is an extended structure (f 115-A˚ long) that is kinked
and twisted at the domain boundaries (Fig. 4). The IgD, or
D1, domain is linked at an approximate 45j angle (and
twist) to the D2 domain through a proline-rich linker, which
has been compared to the linker between the V and C
domains of an antibody. The structure of the IgD is a
seven-stranded h-sandwhich module which adopts a non-
canonical h-type Ig-fold, although it is most structurally
similar to Ig-domains from variable regions of T cell
receptors and antibodies (Fig. 4) [56]. There is a 4-on-3
Fig. 3. Crystal structure of vIL-6 in complex with the gp130-D1D2D3 [31].
(A) Side view. In this orientation, the D3 domains are underneath the
cytokines and therefore not visible. (B) Tilted space-filling view where all
domains are in view.
Fig. 4. Structure of the gp130-D1D2D3 fragment from the complex (shown
in Fig. 3) in the absence of cytokine. For this figure, the rest of the structure
was removed and only the gp130 is shown. The spatially distinct site II and
site III binding sites are labeled.
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sheet arrangement of the order a-b-d-e on c-cV-f-g. Although
there is a short cVstrand, which would place it in the v-type
fold, there are only 12 amino acids between the start of the c
strand and the start of the e strand, placing it in the h-type
category. A DALI search of the D1 resulted in the highest Z-
scores for both v- and h-type Ig-folds. Hence, the gp130 D1
is best considered a hybrid of a v- and h-type Ig-fold, with a
short c-cVstrand. The structure of the gp130 IgD differs
substantially from the s-type D1 of the nonsignalling IL-12
p40 in a manner that reflects the direct interaction of the
gp130 IgD with cytokine [36]. In the p40 subunit of IL-12,
the D1 domain is largely irregular and shows substantial
regions of flexibility. In gp130, the IgD contains an unusual
disulfide bond at its N-terminus between cysteines 6 and 32,
which tethers the A-strand to the B strand, and represents
the point at which the N-terminus departs from the D1 A/B
h-sheet to form a sheet-like contact with the A/B loop of
vIL-6 (discussed below). The AB and EF loops of D1 form
an extensive hydrophobic interface with the BC and FG
loops of D2, indicating that there is limited segmental
flexibility between the domains and that the relative dispo-
sitions of D1 and D2 do not vary to the extent of the ‘‘elbow
angle’’ of antibodies.
The CHR (D2 and D3) of gp130 is composed of two h-
sandwich, fibronectin type-III domains connected at an
approximately 80j angle to form an elbow (Fig. 4). Com-
parison of the CHR with a previously determined crystal
structure of an unliganded gp130 CHR [38], reveals a
remarkable structural coincidence: there are essentially no
conformational differences in the exposed loops and side-
chains of the cytokine-binding site (root mean square devia-
tion (RMSD): 0.72 A˚ for all Ca, 0.976 A˚ for all atoms),
including the double h-bulge structure and extended k-
cation stacking arrangement of the signature WSXWS box.
Contrary to other hematopoietic receptor CHRs [57], the
gp130 CHR appears to be a highly rigid structure which does
not structurally adapt to cytokine. The cross-reactivity of
gp130, then, is due to alternative mechanisms. Further, the
previous CHR structure was of material derived from E. coli,
whereas the material for the vIL-6/gp130 complex is derived
from insect cells. The almost exact superposition of the
common domains indicates that no artifacts of the different
expression systems affect the analysis of the structures.
Overall, the large interaction surfaces between both the
D1/D2 and D2/D3 domains limit segmental flexibility
between the modules (Fig. 4). Hence, ordering of these
domains does not present a conformational entropy barrier
to assembly of the signalling complex. The rigidity of the
gp130 D1D2D3 (CHR-IgD) segment may be a mechanism
to sensitively transmit extracellular orientational changes to
the intracellular domains, which would otherwise be damp-
ened out by inter-domain flexibility. The rigidity of gp130 is
in contrast to the flexible CHR of other hematopoietic
receptors, such as EPO and hGH, which have been crystal-
lized showing some variance in the elbow angle of the CHR
[19,48].
9. Site I
The classical site of interaction of a-receptors with
gp130-cytokines is known as site I, and has been mapped
to the faces of the B and D helices. Since vIL-6 action can
be independent of Ra, it was not required for crystallization
of the complex with gp130. However, by analogy with
human IL-6, the location of where site I would be is clear.
The outward helical face of vIL-6 (B and D helices), where
huIL-6 would interact with Ra (site I), is unoccupied, but
openly accessible in the complex (Figs. 3 and 6), clarifying
both the Ra-independence of vIL-6 and the location of Ra
in the human signaling complexes. The position of site I
satisfies biochemical and mutagenesis studies, indicating
that its role in human IL-6 is to ‘‘present’’ the cytokine to
gp130 (discussed further below). It is clear from the
peripheral location of site I that the Ra in the human
complex is not integral to the core of the signalling as-
sembly, but rather, participates only in the recognition of the
human cytokine’s site II by the gp130 CHR. Recent studies
have shown that, although vIL-6 does not require Ra, its
activity can be enhanced by the presence of the human IL-
6Ra on the surface of cells expressing gp30. While bio-
chemical studies are required to assess whether Ra can bind
to vIL-6, the analogous site I of vIL-6 does contain an
Arginine which has been mapped as a critical determinant
for Ra binding in human IL-6 [21].
10. Shape complementarity in the site II interface
The site II contact surface between vIL-6 and the gp130
CHR is primarily composed of hydrophobic interactions
between the vIL-6 A and C helices, and the CD and EF
loops of the gp130 D2 domain and BC loop of the D3
domain (Fig. 5A). A total of 13 vIL-6 residues and 17
gp130 contact residues bury a total of 1194 A˚2, with only
two H-bonds in the interface. There is an exquisite shape
complementarity between the cytokine and receptor, in
which the protruding gp130 ‘‘elbow’’ slots into a diagonal
groove on a concave face of vIL-6 created by the crossing
angle of the A and C helices. It had been previously spec-
ulated that a conserved concave/convex complementarity
might exist between gp130 cyokines and gp130, respec-
tively [30,35]. This does, indeed, appear to be the case. For
instance, the site II surface of OSM contains a dimple
centered on Gly120 that is centered between the A and C
helices [35]. In the vIL-6 site II interface, a highly con-
served Phe169 protrudes into a cavity on the cytokine sur-
face that is in the same location as the dimple seen in OSM.
This knob-in-hole packing likely underlies the site II rec-
ognition mode across all gp130-cytokines. Thus, one basis
for the cross-reactivity of gp130 for the different cytokines
might be a conservation of ‘‘shape’’ in the site II epitope
amongst the cytokines possessing almost entirely different
amino acids in the site II contact region. Interestingly, none
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of the site II vIL-6 residues which contact gp130 is the same
in human IL-6, which underscores the idea of a general
shape selection.
Hydrophobic amino acids within the core of the interface
may represent the energetic ‘‘hotspots’’ of the site II inter-
face (Fig. 5A). So far, both hydrophobic cluster and charged
interactions have been seen in cytokine receptor complexes,
as exemplified by hGH and IL-4, respectively [15,58]. In
the case of vIL-6/gp130, the hydrophobic cluster mode
appears to predominate, although there are H-bonds at the
lateral poles of the interface which may ‘‘steer’’ the proper
docking orientation for the complementary shapes. The core
of the interface is dominated by a hydrophobic cluster
composed of Trp18 on the vIL-6 A helix and Tyr168–
Phe169 on the EF loop of the gp130 D2, and Val230 on the
D3 BC loop. The vIL-6 Trp18 and gp130 Phe169 protrude
into mutually complementary pockets.
11. The site III interface
Gp130-cytokines possess a third, or ‘‘site III’’ func-
tional epitope, which is necessary for receptor activation,
but the nature of its interaction with gp130 has been
unclear [28,30]. In the structure of the vIL-6/gp130 com-
plex, the site III interaction is comprised of an extensive
interface between the tips of the vIL-6 four-helix bundle
(A/B loop and start of D-helix) and the edge (GF strands)
of the upper three-stranded h-sheet of the gp130 IgD (D1)
domain (Fig. 5B) [31]. The complementary shape of the
interface is formed by the convex torpedo-like tip of vIL-6
resting in a concave depression formed by the curvature of
the upper D1 h-sheet (Fig. 5A–C). This is in contrast to
site II where the convex gp130 elbow docks into a
concave groove on the cytokine (Fig. 5A). The interface
is discontinuous, and is composed of two separate struc-
tural elements on vIL-6: residues in the A/B loop (we term
site IIIa), and the start of the D-helix (we term site IIIb)
(Fig. 5B). These loops primarily interact with the G h-
strand, and to a lesser extent the F, A, and cVstrands of the
receptor D1 Ig h-sandwhich. This region of an Ig-domain
has not been previously seen as a ligand-binding site. A
total of 1641 A˚2 of surface is buried in the interface, and is
partitioned on vIL-6 into 60% from the A/B loop (site IIIa)
and 40% from the D helix (site IIIb). The core of the
interface is formed by vIL-6 site IIIb hydrophobic residues
Tyr143, Trp144, and Phe148 packing into a depression on the
surface of the G strand. In site IIIa, the vIL-6 A/B loop,
usually disordered in uncomplexed cytokines, ‘‘collapses’’
into the gp130 IgD and forms an almost continuous
interaction from residues vIL-6 residues 31 to 49 (Fig.
5B). There are numerous H-bonds formed in this contact,
the majority of which are between main chain N and CO
atoms. Interestingly, the N-terminal four residues of the
IgD, prior to the unusual AB inter-strand disulfide (Cys6–
Cys32), form a strand-like interaction with A/B loop
residues 44–49 of vIL-6 (Fig. 5B). We do not know the
functional significance of this unexpected contact, but it is
known that modifications to the N-terminus of gp130 are
disruptive to signalling [59].
Structure–function studies on gp130-cytokines implicate
a large hydrophobic residue at the N-terminus of the D-helix
as being critical to a functional site III [27,28,35,40]. In
particular, a critical Trp157 in human IL-6 (Phe160 in OSM,
CNTF, and LIF), is present at the identical position (Trp144)
in the vIL-6 structure, placing it in the center of the interface
Fig. 5. Close-up views of the site II (A—left) and site III (B—right)
cytokine– receptor interfaces. Key residues are labeled. Note that for the
site II, there is a concave/convex complementarity for cytokine/receptor
complementarity, and the reverse is true for site III. This feature has also
been predicted for other gp130-cytokines [35].
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(Fig. 5B), where it buries the largest fraction of surface area
of all residues in site III, and makes a hydrogen bond with
Asn92 of the IgD. In fact, Trp144 is only one of four vIL-6
contact residues in the site III interface which correspond to
an identical amino acid in huIL-6 (out of a total of 13).
Hence, the vIL-6 molecular mimicry of the huIL-6 site III is
achieved through preservation of an identical central core
residue (Trp144) which likely is the ‘‘hotspot’’ of the inter-
face, but a different set of peripheral contact residues (9 of
13 vIL-6 contact residues differ). Similar to site II, although
less pronounced, there is a trend for substitution of polar
residues in huIL-6 with hydrophobic amino acids at the
corresponding positions of vIL-6 contacting D1: five hydro-
phobic contact residues on vIL-6 are polar or charged in
huIL-6. This difference is rationalized by the fact that,
although the site II epitope on vIL-6 is enhanced to enable
independence from Ra, binding to site III is likely similar
for the viral and human homologues since this interaction
site is structurally independent of site II engagement for
both cytokines.
12. Extracellular signaling assembly
The composition and architecture of gp130-cytokine
signalling assemblies have been the subject of debate
[21,29,37,46]. The IL-6 system has received the most
attention due to the fact that gp130 was originally cloned
as the IL-6 h receptor, and IL-6 also plays a key role in
multiple myeloma, where it is a prime target for inhibition
[7,24]. Functional and biochemical studies indicate that the
IL-6 signalling assembly consists of a ‘‘hexamer’’ contain-
ing two huIL-6, two Ra, and two gp130 (2:2:2) [40,45,60].
Using analytical ultracentrifugation and gel filtration, we
clearly see evidence for a tetramer of vIL-6/gp130 (2:2) and
a hexamer of huIL-6/Ra/gp130 (2:2:2). In the structure of
the vIL-6/gp130 tetramer, the Ra-independent site I faces of
vIL-6 are unoccupied, but sterically open and accessible
(Fig. 6A). In huIL-6, the two analogous site I faces would
each be occupied by an Ra in a manner similar to the site I
interaction between hGH and human growth hormone
receptor (GH-R), creating the hexameric structure (Fig. 2A).
Fig. 6. A schematic showing a topological diagram of (A) the correct gp130 signaling assembly, and (B) a hypothetical model of the human IL-6 signaling
complex (see text for details of the modeling).
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We constructed a theoretical model of the gp130-cyto-
kine hexameric signaling assembly (Fig. 6B). The template
for the model is the vIL-6/gp130 tetramer structure con-
taining two gp130 molecules (D1D2D3) in blue and green,
and two cytokine molecules in pink and red. The modeled
locations of the two a-receptors (Ra) are indicated by the
purple molecular surfaces bound to the site I epitopes of
the two cytokines (Fig. 6B). With the two Ra occupying
the site I epitope of the cytokines, the hexameric assembly
is complete. For the model of Ra, the crystal structure of
the CHR of the GH-R was used (PDB ID: 1HHR) [15]. To
place the Ra onto the site I epitope of the cytokine to
produce the hexamer, the site I complex of hGH and GH-
R (1:1) was aligned to the vIL-6/gp130 tetramer by
superimposing the four-helix bundles of vIL-6 and hGH
(PDB ID: 1A22). The GH-R then occupied the site I face
of the cytokine, and was subsequently adjusted to max-
imize interaction with site I contact positions which have
been mapped by mutagenesis onto gp130-cytokines. In this
way, the Ra is complexed to the cytokine in an identical
fashion as the GH-R is complexed to the site I face of
hGH, which is likely a close approximation. This align-
ment results in substantial contact between the bases of the
Ra and the D3 domain of gp130, which is also seen in the
homo-dimeric receptor complex of hGH and GH-R as a
means of recruiting the second receptor to the hGH site II
face [15]. The affinity-enhancing effect of Ra is likely
provided by receptor–receptor contact between the base
(D3) of the Ra and the base (D3) of the gp130 CHR, as
seen in the hGH/GH-R homo-dimer structure [61], which
will bolster the inadequate affinity of the site II face of
huIL-6 for the CHR binding site. The human a-receptors
(Ra) also contain a D1 domain, however, it does not play
an important functional role in either recognition or acti-
vation, and so was not modeled. The disposition of
gp130’s three-membrane proximal FN-III domains leading
to the cell surface cannot be modeled with certainty. A
structural model of four tandem FN-III domains indicates a
rigid, rod-like, extended structure [62]. However, func-
tional studies implicate the fifth FN-III domain as being
involved in a homo-dimeric contact with the adjoining fifth
FN-III domain of the second receptor, which would
necessitate a bend between the gp130 D3 and D4 to angle
the three FN-III domains back towards each other. Hence,
we can propose a model for the huIL-6 hexameric assem-
bly which rationalizes the structural and functional data
(Fig. 6B). One question that arises from this hexameric
model is whether cytokine binding to sites II and III may
be ‘‘coupled’’ in such a way that interaction with site II
cannot occur in the absence of site III. We tested this
possibility by reconstituting the minimal site II ‘‘recogni-
tion’’ complex between huIL-6, Ra, and the CHR of
gp130 (minus IgD) [45]. This assembly formed a stable
hetero-trimer (1IL-6, 1 Ra, 1 gp130 CHR) in a 1:1:1
stoichiometry, which demonstrates that site II is structur-
ally independent of site III, and may therefore complex
prior to, or coincident with, engagement of site III to
proceed to the hexamer.
The hexamer model directly applies to human IL-11,
which contains three functional epitopes (sites I, II, and III)
and homo-dimerizes two gp130 in an Ra-dependent manner
identical to that of huIL-6 [44]. For IL-11, then, the site I
faces of the cytokine would be occupied by two IL-11Ra to
build up the hexamer (Fig. 6B). The structural and sequence
similarity of IL-12 with the IL-6/gp130 system strongly
suggests that IL-12 signalling may be mediated by a similar
hexameric complex [36]. However, the two gp130s would
be replaced by the analogous IL-12 signal transducers
known as h1 and h2. Other members of the gp130 family,
such as CNTF, LIF, and OSM, hetero-dimerize gp130 with
LIF-R and/or OSM-R [30,37,42,46]. It is not clear from the
symmetric model how an asymmetric hetero-dimerization is
achieved in these assemblies. However, the stoichiometry of
the CNTF signalling assembly has been shown to be a
hexamer (two CNTF, two Ra, one gp130, one LIF-R) [63],
which suggests that the higher-order oligomer will bear a
structural resemblance to the framework we present here for
vIL-6, huIL-6, and huIL-11. However, evidence also exists
for a tetrameric complex of CNTF/CNTF-Ra/gp130 in a
1:1:1:1 stoichiometry [42,46]. There remains a possibility
that the presence of a hexamer or tetramer may depend on
the local concentration of cytokine.
Finally, does the signaling complex we see in the gp130
system have relevance to other cytokine systems? The
GCSF receptor (GCSF-R) is 46% homologous in sequence
to gp130 and has an identical domain structure. The GCSF-
R has six domains, where the D1 is an Ig-like domain,
followed by the CHR at D2D3, followed by three FN-III
domains leading to the membrane. GCSF does not utilize a
shared receptor, such as gp130: GCSF-R is specific for
GCSF and is also a signaling receptor. The classical ‘‘site
II’’ epitope which interacts with the CHR has been defined
both from mutagenesis [64] and a crystal structure of a
complex of GCSF with the CHR of the GCSF-R [14], and
this interaction is highly reminiscent of other cytokine–
CHR complexes. However, it has been known from func-
tional studies that the GCSF-R D1 domain, like gp130, is
required for signaling, but it was not appreciated until
recently that GCSF possesses a bona fide site III [65]. In
the crystal structure of the GCSF/CHR complex, there is a
‘‘side-by-side’’ dimer of 1:1 complexes to form an overall
2:2, which is the predicted stoichiometry of the active
extracellular signaling complex for GCSF with the GCSF-
R [14]. Although this dimer of CHR complexes lacks the
D1, a case was made for this assembly representing the
active signaling complex even though it was topologically
unlikely that a D1 domain could fold back and make further
interactions with the complex [14]. Recently, epitope-map-
ping studies of GCSF binding to GCSF-R defined an
interaction between a ‘‘site III’’ epitope of GCSF with the
D1 domain of GCSF-R, resulting in a model identical in
topology to the vIL-6/gp130 framework (Fig. 6A) [31,65].
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Thus, the utility of spatially distinct functional epitopes on
both cytokine and receptor for assembling an interlocking
dimer has been repeated in a distinct cytokine system. It will
be interesting to see whether other multi-component cyto-
kine receptor systems also use the gp130 framework to
assemble signaling complexes, or whether new solutions to
the problem will emerge.
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